BUND FINANCE › Stocks › COR
Cencora, Inc. (COR)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +6.13% above its 50-day average.
- It is +10.00% above its 200-day average (long-term uptrend).
- It sits at 78% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Revenue | US$238.6B | US$262.2B | US$294.0B | US$321.3B | US$337.4B |
| Net income | US$1.7B | US$1.7B | US$1.5B | US$1.6B | US$3.5B |
| EPS (diluted) | 8.04 | 8.53 | 7.53 | 7.96 | 17.95 |
| Gross margin | 3.2% | 3.0% | 3.0% | 3.2% | 4.1% |
| Operating margin | 1.2% | 0.9% | 1.0% | 1.1% | 1.2% |
| Net margin | 0.7% | 0.7% | 0.5% | 0.5% | 1.0% |
| Free cash flow | US$2.2B | US$3.5B | US$3.0B | US$3.2B | US$3.9B |
| Total debt | US$7.6B | US$6.8B | US$6.7B | US$9.3B | US$11.3B |
| Cash | US$3.5B | US$2.7B | US$3.2B | US$4.4B | US$4.9B |
Compound annual growth: revenue 9.1% · net income 19.7% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 19.4x | 24.5x | 27.1x |
| EV / EBITDA | 11.8x | 12.9x | 16.5x |
| Operating margin | 1.3% | — | 3.6% |
| Net margin | 1.0% | — | -0.0% |
| Debt / equity | 22.66 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products l…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice